Published: July 2004
Pages: 34
Published by: HTStec

Table of Contents

This report summarizes the results of a comprehensive global Pharma/University web-based survey on the assay of transporter activity. The objective was to gain a better understanding of the importance of transporter targets in drug discovery today. The survey set out to collect data on the number of transporter targets screened, data points per screen and costs associated with screening that would assist companies that are trying to bring to the market new technologies for the assay of transporters.

Highlights of this Report:

• A web-based survey on transporter assay trends was undertaken with 61 responses (40 complete and 21 partially filled out) collected from 46 different organisations in 2 weeks.
• Responses were split geographically between North America – 22, Europe – 38 and Japan - 1.
• Survey respondents represented 36 Pharma/Biotechs, 20 University/Research Institutes, 2 Contract Service Organizations, 2 Agrochemical Companies and 1 Food Industry Company.
• Survey respondents represented 20 basic/academic research labs, 11 assay development and primary screening (HTS) labs, 10 leads-to-candidate (ADME/Tox and preclinical research) labs, 9 therapeutic area labs, 6 compound profiling labs, 3 secondary screening labs and 2 full drug discovery labs.
• Survey results were expressed as the average response of survey respondents from Pharma and University/Research Institutes and comparisons made between the two groups.
• 73% of Pharma respondents and 100% of University/Research respondents view transporters as an independent target class.
• Pharma R and D efforts on transporters seem to be relatively evenly distributed across all areas of the drug discovery process.
• The report details respondents’ feedback on classes of transporters under active investigation and those that might be pharmaceutically relevant.
• 77% of all Pharma surveyed currently undertake or plan to undertake the primary screening of transporters targets.
• The mean number of primary transporter screens undertaken by Pharma respondents in 2003 was 1.0 screen/year/lab with 349K wells (data points) per screen.
• Globally it is estimated that 203 transporter primary screening campaigns will be performed in 2004.
• The Pharma market for transporter primary screening reagents is estimated to be US$7.7Million in 2004, with an annual growth rate of 94%.
• The mean budget allocated per lab for ion channel profiling in 2004 was estimated to be US$270K in house versus US$82K for outsourced profiling.
• Transporter targets were also evaluated in other areas of drug discovery outside of primary screening.
• 20% of Pharma respondents surveyed indicated they currently outsource transporter-related evaluations.

Purchase report >>